KR100525809B1 - 아미드 화합물 - Google Patents

아미드 화합물 Download PDF

Info

Publication number
KR100525809B1
KR100525809B1 KR10-2001-7007314A KR20017007314A KR100525809B1 KR 100525809 B1 KR100525809 B1 KR 100525809B1 KR 20017007314 A KR20017007314 A KR 20017007314A KR 100525809 B1 KR100525809 B1 KR 100525809B1
Authority
KR
South Korea
Prior art keywords
compound
reaction
mixture
dichloromethane
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR10-2001-7007314A
Other languages
English (en)
Korean (ko)
Other versions
KR20010093819A (ko
Inventor
야마다아키라
아오키사토시
Original Assignee
후지사와 야꾸힝 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 후지사와 야꾸힝 고교 가부시키가이샤 filed Critical 후지사와 야꾸힝 고교 가부시키가이샤
Publication of KR20010093819A publication Critical patent/KR20010093819A/ko
Application granted granted Critical
Publication of KR100525809B1 publication Critical patent/KR100525809B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR10-2001-7007314A 1999-01-14 2000-01-06 아미드 화합물 Expired - Lifetime KR100525809B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPP8180 1999-01-14
AUPP8180A AUPP818099A0 (en) 1999-01-14 1999-01-14 New n-containing heterocyclic compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR10-2004-7009661A Division KR100520406B1 (ko) 1999-01-14 2000-01-06 아미드 화합물을 포함하는 약제학적 조성물

Publications (2)

Publication Number Publication Date
KR20010093819A KR20010093819A (ko) 2001-10-29
KR100525809B1 true KR100525809B1 (ko) 2005-11-03

Family

ID=3812385

Family Applications (2)

Application Number Title Priority Date Filing Date
KR10-2001-7007314A Expired - Lifetime KR100525809B1 (ko) 1999-01-14 2000-01-06 아미드 화합물
KR10-2004-7009661A Expired - Lifetime KR100520406B1 (ko) 1999-01-14 2000-01-06 아미드 화합물을 포함하는 약제학적 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR10-2004-7009661A Expired - Lifetime KR100520406B1 (ko) 1999-01-14 2000-01-06 아미드 화합물을 포함하는 약제학적 조성물

Country Status (21)

Country Link
US (2) US6710043B1 (enExample)
EP (1) EP1140836B1 (enExample)
JP (2) JP3617454B2 (enExample)
KR (2) KR100525809B1 (enExample)
CN (1) CN1142910C (enExample)
AR (1) AR028812A1 (enExample)
AT (1) ATE502923T1 (enExample)
AU (1) AUPP818099A0 (enExample)
BR (1) BRPI0008753B8 (enExample)
CA (1) CA2360360C (enExample)
CZ (1) CZ20012562A3 (enExample)
DE (1) DE60045759D1 (enExample)
ES (1) ES2363492T3 (enExample)
HK (1) HK1044337B (enExample)
HU (1) HU230422B1 (enExample)
IL (2) IL143841A0 (enExample)
RU (1) RU2208608C2 (enExample)
TR (1) TR200102038T2 (enExample)
TW (1) TWI229075B (enExample)
WO (1) WO2000042011A1 (enExample)
ZA (1) ZA200104713B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344358B1 (en) * 1999-05-28 2002-02-05 Fujisawa Pharmaceutical Co., Ltd. Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property
UY27003A1 (es) 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer
JPWO2002045715A1 (ja) * 2000-12-07 2004-04-08 藤沢薬品工業株式会社 抗痴呆効果増強剤
WO2003049736A1 (en) * 2001-12-11 2003-06-19 Sepracor, Inc. 4-substituted piperidines, and methods of use thereof
CN100340167C (zh) * 2002-12-06 2007-10-03 陶氏农业科学公司 增效组合物
WO2004089296A2 (en) 2003-04-03 2004-10-21 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
CA2559665A1 (en) 2004-03-16 2005-09-29 The Regents Of The University Of California Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
NZ554555A (en) 2004-10-20 2011-09-30 Univ California Cyclohexyl-urea derivatives as improved inhibitors for the soluble epoxide hydrolase
CA2579227A1 (en) * 2004-11-04 2006-05-18 Neurogen Corporation Arylalkyl ureas as cb1 antagonists
ES2348332T3 (es) 2005-09-16 2010-12-02 Arrow Therapeutics Limited Derivados de bifenilo y su uso en el tratamiento de la hepatitis c.
AR059826A1 (es) * 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
US8247442B2 (en) 2006-03-29 2012-08-21 Purdue Pharma L.P. Benzenesulfonamide compounds and their use
US8791264B2 (en) 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
WO2007118854A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and the use thereof
JP2010507587A (ja) * 2006-10-20 2010-03-11 アレテ セラピューティクス， インコーポレイテッド 可溶性エポキシドヒドロラーゼ阻害剤
WO2008051873A2 (en) * 2006-10-20 2008-05-02 Arete Therapeutics, Inc. Phenylurea compounds as soluble epoxide hydrolase inhibitors
GB0706793D0 (en) * 2007-04-05 2007-05-16 Evotec Ag Compounds
US8399486B2 (en) 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
US8637544B2 (en) 2007-04-20 2014-01-28 Senju Pharmaceutical Co., Ltd. Neurite formation promoter
WO2009040659A2 (en) 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
SI2207775T1 (sl) 2007-11-05 2012-05-31 Novartis Ag benzilamino karboksiacil piperidinski derivati kot inhibitorji CETP uporabni za zdravljenje bolezni kot je hiperlipidemija ali arterioskleroza
EP2404901B1 (en) 2007-12-03 2013-05-22 Novartis AG 1,2-Disubstituted 4-benzylamino-pyrrolidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
GB0813144D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB0813142D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
US8946197B2 (en) 2009-11-16 2015-02-03 Chdi Foundation, Inc. Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof
WO2012054093A2 (en) 2010-01-29 2012-04-26 The Regents Of The University Of California Acyl piperidine inhibitors of soluble epoxide hydrolase
US8889716B2 (en) 2011-05-10 2014-11-18 Chdi Foundation, Inc. Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0308337A2 (en) * 1987-09-17 1989-03-22 Mitsubishi Kasei Corporation 4-Aminopyridine derivatives and their acid addition salts
WO1997028141A1 (fr) * 1996-02-02 1997-08-07 Pierre Fabre Medicament Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4939679B1 (enExample) 1969-06-30 1974-10-28
US3647805A (en) * 1969-07-11 1972-03-07 Kyorin Seiyaku Kk Benzoylamino substituted 1-benzoyl-piperidines
BE791501A (fr) 1971-11-19 1973-05-17 Albert Ag Chem Werke Diamines cycliques n,n'-disubstituees et leur procede de preparation
GB1416872A (en) 1972-03-10 1975-12-10 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
JPS5152176A (enExample) 1974-10-12 1976-05-08 Yoshitomi Pharmaceutical
EP0002401B1 (fr) 1977-11-24 1980-12-10 Synthelabo Dérivés de naphtalène, leur préparation et leur application en thérapeutique
DE3544244A1 (de) * 1985-12-14 1987-06-25 Minnesota Mining & Mfg Vorrichtung zum entnehmen von fuellgut aus beuteln
US4886809A (en) 1986-07-31 1989-12-12 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and salts thereof
CA1322199C (en) 1987-07-15 1993-09-14 Masami Eigyo N-¬(2-oxopyrrolidin-1-yl) acetyl)| piperazine derivatives and drug for senile dementia
US5346907A (en) * 1988-04-05 1994-09-13 Abbott Laboratories Amino acid analog CCK antagonists
GB8917687D0 (en) 1989-08-02 1989-09-20 Fujisawa Pharmaceutical Co Aminopiperazine derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
RU2024507C1 (ru) * 1991-11-18 1994-12-15 Евгений Яковлевич Левитин 5-хлор-2-пиридиламид-4-нитро-n-(карбоксиметил)антраниловой кислоты, проявляющий противовоспалительную активность
CA2077252C (en) 1992-08-31 2001-04-10 Khashayar Karimian Methods of making ureas and guanidines, and intermediates therefor
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
ATE219766T1 (de) * 1993-04-07 2002-07-15 Otsuka Pharma Co Ltd N-acylierte 4-aminopiperidin derivate als aktive bestandteile von peripher gefässerweiternden wikstoffen
CA2123728A1 (en) 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
DE4319038A1 (de) 1993-06-08 1994-12-15 Bayer Ag Verwendung von teilweise bekannten substituierten Chromanen als Arzneimittel, neue Wirkstoffe und Verfahren zu ihrer Herstellung
KR100324040B1 (ko) * 1993-06-18 2002-07-22 후지사와 야꾸힝 고교 가부시키가이샤 합성적 용도로 사용하기 위한 신규한 중간체 및아미노피페라진유도체를제조하는방법
US5500423A (en) 1994-09-09 1996-03-19 Hoechst-Roussel Pharmaceuticals Inc. 5,6-dihydro-4H-imidazo[4,5,1-ij]quinolines
IL117805A0 (en) 1995-04-07 1996-08-04 Schering Corp Carbonyl piperazinyl and piperidinyl compounds
GB9519077D0 (en) * 1995-09-18 1995-11-15 Fujisawa Pharmaceutical Co New heterocyclic compounds
EP0873117A4 (en) 1995-11-13 1999-02-24 Smithkline Beecham Corp HEMOREGULATORY CONNECTIONS
ZA9710872B (en) 1996-12-12 1998-06-15 Fujisawa Pharmaceutical Co N-(4-acetyl-1-piperazinyl)-4-fluorobenzamide hydrate.
WO1998027930A2 (en) 1996-12-24 1998-07-02 Fujisawa Pharmaceutical Co., Ltd. New use of aminopiperazine derivatives
WO1998035951A2 (en) 1997-02-17 1998-08-20 Fujisawa Pharmaceutical Co., Ltd. New aminopiperazine derivatives
US6344358B1 (en) * 1999-05-28 2002-02-05 Fujisawa Pharmaceutical Co., Ltd. Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0308337A2 (en) * 1987-09-17 1989-03-22 Mitsubishi Kasei Corporation 4-Aminopyridine derivatives and their acid addition salts
WO1997028141A1 (fr) * 1996-02-02 1997-08-07 Pierre Fabre Medicament Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments

Also Published As

Publication number Publication date
ATE502923T1 (de) 2011-04-15
KR20010093819A (ko) 2001-10-29
HK1044337B (zh) 2004-11-26
CZ20012562A3 (cs) 2001-11-14
EP1140836A1 (en) 2001-10-10
HUP0105108A2 (hu) 2002-05-29
KR20040063001A (ko) 2004-07-09
HUP0105108A3 (en) 2002-11-28
EP1140836B1 (en) 2011-03-23
HU230422B1 (hu) 2016-05-30
JP2004002414A (ja) 2004-01-08
ZA200104713B (en) 2002-09-09
IL143841A (en) 2006-07-05
AUPP818099A0 (en) 1999-02-11
CN1142910C (zh) 2004-03-24
JP3617454B2 (ja) 2005-02-02
BR0008753A (pt) 2001-11-06
ES2363492T3 (es) 2011-08-05
JP2002534503A (ja) 2002-10-15
AR028812A1 (es) 2003-05-28
WO2000042011A1 (en) 2000-07-20
TWI229075B (en) 2005-03-11
CN1336917A (zh) 2002-02-20
BR0008753B1 (pt) 2013-11-12
RU2208608C2 (ru) 2003-07-20
CA2360360A1 (en) 2000-07-20
CA2360360C (en) 2009-09-08
US6710043B1 (en) 2004-03-23
TR200102038T2 (tr) 2002-01-21
US20040014745A1 (en) 2004-01-22
DE60045759D1 (de) 2011-05-05
BRPI0008753B8 (pt) 2021-05-25
IL143841A0 (en) 2002-04-21
HK1044337A1 (en) 2002-10-18
KR100520406B1 (ko) 2005-10-11

Similar Documents

Publication Publication Date Title
KR100525809B1 (ko) 아미드 화합물
US6291464B1 (en) Aminopiperazine derivatives
ES2240339T3 (es) Derivados de oxibenzamidas en calidad de inhibidores de factor xa.
AU675928B2 (en) Opioid diarylmethylpiperazines and piperidines
KR19990022448A (ko) 벤즈아미드 유도체 및 바소프레신 길항제로서의 그의 용도
US7612076B2 (en) Piperazinyl-pyridine derivatives
CA2258093A1 (en) Fibrinogen receptor antagonists
AU2003256069A1 (en) Process for preparing quinolin antibiotic intermediates
CN101679370A (zh) 香草素受体配体及其在制备药物中的用途
JP2002517480A (ja) インテグリンインヒビターとしてのフェニルアラニン誘導体
EP0923555A1 (en) Carboxamide derivatives of pyrrolidine, piperidine and hexahydroazepine for the treatment of thrombosis disorders
ES2295150T3 (es) Derivados de enamina como moleculas de adhesion celular.
KR100620406B1 (ko) 콜린작용 활성을 강화시키기 위한 아미드 화합물
WO2003028725A1 (en) 4-(1-piperidiny)-butylcarboxamide as d3 dopamine receptor subtype selective ligands
KR20140049028A (ko) 바닐로이드 수용체 리간드로서의 치환된 바이사이클릭 방향족 카복스아미드 및 우레아 유도체
ES2344546T3 (es) Compuesto aliciclico sustituido con arilo y composicion farmaceutica que lo contiene.
KR950014568B1 (ko) 융합된 이미다조헤테로사이클릭 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물
AU760434B2 (en) Amide compounds
KR20140085470A (ko) 바닐로이드 수용체 리간드로서의 아민 치환된 메탄설폰아미드 유도체
ES2396557T3 (es) Derivado de benciloxipropilamina
JP2008521874A (ja) グリコーゲンホスホリラーゼのインヒビターとして有用なピロロピリジン−２−カルボン酸アミド誘導体
JP2003535088A (ja) ２，７−ナフチリジン誘導体
JP2003535081A (ja) ３−置換イソキノリン−１−イル誘導体
MXPA01006630A (en) Amide compounds

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20010612

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20030627

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20040223

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20030627

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20040524

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20040223

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20050630

Appeal identifier: 2004101002231

Request date: 20040524

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20040618

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20040618

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20040524

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20030827

Patent event code: PB09011R02I

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial

Comment text: Report of Result of Re-examination before a Trial

Patent event code: PB06011S01D

Patent event date: 20040730

J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20040524

Effective date: 20050630

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20050701

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20040524

Decision date: 20050630

Appeal identifier: 2004101002231

PS0901 Examination by remand of revocation
S901 Examination by remand of revocation
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20050712

Patent event code: PE09021S01D

GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

Patent event date: 20051012

Patent event code: PS07012S01D

Comment text: Decision to Grant Registration

Patent event date: 20050705

Patent event code: PS07011S01I

Comment text: Notice of Trial Decision (Remand of Revocation)

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20051026

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20051027

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20081010

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20091009

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20101020

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20110920

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20121002

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20121002

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20131001

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20131001

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20141007

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20141007

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20151002

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20151002

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20160929

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20160929

Start annual number: 12

End annual number: 12

PC1801 Expiration of term

Termination date: 20200706

Termination category: Expiration of duration